➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
AstraZeneca
Moodys
Mallinckrodt
Medtronic

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Claims for Patent: 7,560,429

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,560,429
Title:Orodispersible dosage forms of desmopressin acetate
Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
Inventor(s): Nilsson; Anders (Lund, SE), Lindner; Hans (Leichlingen, DE), Wittendorff; Jorgen (Hvidovre, DK)
Assignee: Ferring B.V. (Hoofddorp, NL)
Application Number:10/513,437
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,560,429
Patent Claims: 1. An orodispersible solid pharmaceutical dosage form of desmopressin acetate, wherein said dosage form (A) disintegrates in the mouth within 10 seconds and (B) comprises an amount of desmopressin, measured as the free base, selected from the group consisting of 25 .mu.g, 50 .mu.g and 75 .mu.g.

2. A dosage form as claimed in claim 1, wherein the dosage form comprises desmopressin acetate and an open matrix network carrying the desmopressin acetate, wherein the open matrix network is comprised of a water-soluble or water-dispersible carrier material that is inert towards desmopressin acetate.

3. A dosage form as claimed in claim 2, wherein the open matrix network comprises gelatin.

4. A dosage form as claimed in claim 3, wherein the gelatin is fish gelatin.

5. A dosage form as claimed in claim 4, wherein the fish gelatin is non-gelling.

6. A process for preparing an orodispersible solid pharmaceutical dosage form of desmopressin acetate which disintegrates in the mouth within 10 seconds and which comprises an amount of desmopressin, measured as the free base, selected from the group consisting of 25 .mu.g, 50 .mu.g and 75 .mu.g, said process comprising subliming solvent from a composition comprising desmopressin acetate and a solution of carrier material in the solvent, wherein the composition is in the solid state in a mold.

7. A process as claimed in claim 6, wherein the subliming is carried out by freeze drying the composition.

8. A process as claimed in claim 6, wherein the solvent is water.

9. A process as claimed in claim 6, wherein the pH of the solution is within the range of from 3 to 6.

10. A method of treating a disease or condition selected from the group consisting of incontinence, primary nocturnal enuresis (PNE), nocturia and central diabetes insipidus, comprising administering to a subject an effective and generally non-toxic amount of desmopressin acetate in an orodispersible solid pharmaceutical dosage form, wherein said dosage form (A) disintegrates in the mouth within 10 seconds and (B) comprises an amount of desmopressin, measured as the free base, selected from the group consisting of 25 .mu.g, 50 .mu.g and 75 .mu.g.

11. A packaged dosage form of desmopressin acetate comprising an orodispersible solid pharmaceutical dosage form of desmopressin acetate, wherein said dosage form disintegrates in the mouth within 10 seconds, and wherein said dosage form comprises an amount of desmopressin, measured as the free base, selected from the group consisting of 25 .mu.g, 50 .mu.g and 75 .mu.g, together with instructions to place the dosage form in a subject's mouth.

12. A method for preparing a packaged dosage form of desmopressin acetate, the method comprising bringing into association an orodispersible solid pharmaceutical dosage form of desmopressin acetate, wherein said dosage form disintegrates in the mouth within 10 seconds, and wherein said dosage form comprises an amount of desmopressin, measured as the free base, selected from the group consisting of 25 .mu.g, 50 .mu.g and 75 .mu.g, and instructions to place the dosage form in a subject's mouth.

13. A process as claimed in claim 6, wherein the pH of the solution is within the range of from 3.5 to 5.5.

14. A process as claimed in claim 6, wherein the pH of the solution is within the range of from 4 to 5.

15. An orodispersible solid pharmaceutical dosage form of desmopressin acetate, wherein said dosage form (i) disintegrates in the mouth within 10 seconds, (ii) comprises an amount of desmopressin, measured as the free base, selected from the group consisting of 25 .mu.g, 50 .mu.g and 75 .mu.g, and (iii) is prepared by a process comprising subliming solvent from a composition comprising desmopressin acetate and a solution of carrier material in the solvent, wherein the composition is in the solid state in a mold.

16. A dosage form as claimed in claim 15, wherein the subliming is carried out by freeze drying the composition.

17. A dosage form as claimed in claim 15, wherein the solvent is water.

18. A dosage form as claimed in claim 15, wherein the pH of the solution is within the range of from 3 to 6.

19. A dosage form as claimed in claim 15, wherein the pH of the solution is within the range of from 4 to 5.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Harvard Business School
McKinsey
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.